Sign in

    Dennis Kennedy

    Research Analyst at LifeSci Capital

    Dennis Kennedy is Vice President and Research Analyst at LifeSci Capital LLC, specializing in the healthcare and life sciences sector. He currently covers three companies and has maintained a 100% success rate on TipRanks, with an overall analyst ranking of 3719 and a 3.31-star rating. Kennedy joined LifeSci Capital in early 2025 and has held the Vice President, Research Analyst position for over five months, previously building experience across related investment roles. He possesses relevant professional credentials, including FINRA registration and securities licenses, underpinning his achievements as a ranked Wall Street analyst known for consistent, high-performing calls in his coverage universe.

    Dennis Kennedy's questions to Scholar Rock Holding (SRRK) leadership

    Dennis Kennedy's questions to Scholar Rock Holding (SRRK) leadership • Q1 2025

    Question

    Dennis Kennedy asked for expectations for the tirzepatide monotherapy arm in the EMBRAZE study, specifically regarding the extent of lean mass loss by week 24 and whether the 8-week follow-up is sufficient to observe weight regain.

    Answer

    President of R&D Akshay Vaishnaw explained that they expect the tirzepatide arm to show lean mass loss consistent with historical data, around 25-30% of total weight loss at 24 weeks. He acknowledged the 8-week follow-up is short but stated the trajectory of weight change between the study arms during that period will still provide important insights.

    Ask Fintool Equity Research AI